Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Rating of “Hold” by Analysts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) has been assigned an average rating of “Hold” from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month target […]

Leave a Reply

Your email address will not be published.

Previous post Computershare Limited (OTCMKTS:CMSQF) Sees Large Growth in Short Interest
Next post Body of second canoeist recovered in Boundary Waters